{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T21:55:56Z","timestamp":1768341356988,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,30]],"date-time":"2021-10-30T00:00:00Z","timestamp":1635552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,30]],"date-time":"2021-10-30T00:00:00Z","timestamp":1635552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Prostate cancer is one of the most common cancers in men and its incidence has increased dramatically in the last decade. This increase in the detection of this type of cancer is based more on the detection of PSA or PSMA antigens as the most important specific antigens of this cancer, and this early detection has greatly helped in the more optimal treatment of patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Main body<\/jats:title>\n                <jats:p>Many methods have been proposed by researchers for early detection of prostate cancer, but most of the methods used today to detect this type of cancer have been using classical antibodies. Although classical antibodies are able to detect tumor cell markers, but instability, large size, costly and laborious production, and random immobility characteristics, causes many problems. Nanobodies or VHHs, which are derived from camel heavy chain antibodies, have special advantages and have eliminated the disadvantages of classical antibodies which makes them attractive to use in biosensors and cancer diagnostic kits. The research that has been done so far shows that the introduced nanobodies are created for the purpose of targeting, detecting and sensing prostate cancer cells with two main purposes. The first is the efficient identification of prostate cancer and the second is the elimination of cancer cells.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Research shows the use of specific nanobodies against prostate cancer antigens in the design of biosensors and target therapy will be very interesting. In this review article, these nanobodies are introduced and categorized based on their performance.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12935-021-02285-0","type":"journal-article","created":{"date-parts":[[2021,10,30]],"date-time":"2021-10-30T20:16:39Z","timestamp":1635624999000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Nanobodies: a tool to open new horizons in diagnosis and treatment of prostate cancer"],"prefix":"10.1186","volume":"21","author":[{"given":"Maryam","family":"Hosseindokht","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamid","family":"Bakherad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6017-5270","authenticated-orcid":false,"given":"Hamed","family":"Zare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,30]]},"reference":[{"issue":"2","key":"2285_CR1","doi-asserted-by":"publisher","first-page":"169","DOI":"10.5301\/jbm.5000063","volume":"29","author":"H Zare","year":"2014","unstructured":"Zare H, Rajabibazl M, Rasooli I, Ebrahimizadeh W, Bakherad H, Ardakani LS, Gargari SLM. Production of nanobodies against prostate-specific membrane antigen (PSMA) recognizing LnCaP cells. Int J Biol Markers. 2014;29(2):169\u201379. https:\/\/doi.org\/10.5301\/jbm.5000063.","journal-title":"Int J Biol Markers"},{"key":"2285_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-020-05057-6","author":"EA Ruigrok","year":"2020","unstructured":"Ruigrok EA, van Vliet N, Dalm SU, de Blois E, van Gent DC, Haeck J, de Ridder C, Stuurman D, Konijnenberg MW, van Weerden WM. Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy. Eur J Nucl Med Mol Imaging. 2020. https:\/\/doi.org\/10.1007\/s00259-020-05057-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"2285_CR3","doi-asserted-by":"publisher","first-page":"e484","DOI":"10.1016\/S1470-2045(14)70211-6","volume":"15","author":"J Cuzick","year":"2014","unstructured":"Cuzick J, Thorat MA, Andriole G, Brawley OW, Brown PH, Culig Z, Eeles RA, Ford LG, Hamdy FC, Holmberg L. Prevention and early detection of prostate cancer. Lancet Oncol. 2014;15(11):e484\u201392. https:\/\/doi.org\/10.1016\/S1470-2045(14)70211-6.","journal-title":"Lancet Oncol"},{"issue":"3","key":"2285_CR4","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/cmmi.1558","volume":"9","author":"M Evazalipour","year":"2014","unstructured":"Evazalipour M, D\u2019Huyvetter M, Tehrani BS, Abolhassani M, Omidfar K, Abdoli S, Arezumand R, Morovvati H, Lahoutte T, Muyldermans S. Generation and characterization of nanobodies targeting PSMA for molecular imaging of prostate cancer. Contrast Media Mol Imaging. 2014;9(3):211\u201320. https:\/\/doi.org\/10.1002\/cmmi.1558.","journal-title":"Contrast Media Mol Imaging"},{"issue":"23","key":"2285_CR5","doi-asserted-by":"publisher","first-page":"7547","DOI":"10.1021\/ac051092j","volume":"77","author":"D Saerens","year":"2005","unstructured":"Saerens D, Frederix F, Reekmans G, Conrath K, Jans K, Brys L, Huang L, Bosmans E, Maes G, Borghs G. Engineering camel single-domain antibodies and immobilization chemistry for human prostate-specific antigen sensing. Anal Chem. 2005;77(23):7547\u201355. https:\/\/doi.org\/10.1021\/ac051092j.","journal-title":"Anal Chem"},{"key":"2285_CR6","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jpba.2018.06.021","volume":"158","author":"X Liu","year":"2018","unstructured":"Liu X, Wang D, Chu J, Xu Y, Wang W. Sandwich pair nanobodies, a potential tool for electrochemical immunosensing serum prostate-specific antigen with preferable specificity. J Pharm Biomed Anal. 2018;158:361\u20139. https:\/\/doi.org\/10.1016\/j.jpba.2018.06.021.","journal-title":"J Pharm Biomed Anal"},{"issue":"2","key":"2285_CR7","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/bab.1916","volume":"68","author":"H Aghamollaei","year":"2021","unstructured":"Aghamollaei H, Ghanei M, Rasaee MJ, Latifi AM, Bakherad H, Fasihi-Ramandi M, Taheri RA, Gargari SLM. Isolation and characterization of a novel nanobody for detection of GRP78 expressing cancer cells. Biotechnol Appl Biochem. 2021;68(2):239\u201346. https:\/\/doi.org\/10.1002\/bab.1916.","journal-title":"Biotechnol Appl Biochem"},{"issue":"6","key":"2285_CR8","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1089\/hyb.2012.0048","volume":"31","author":"M Evazalipour","year":"2012","unstructured":"Evazalipour M, Tehrani BS, Abolhassani M, Morovvati H, Omidfar K. Camel heavy chain antibodies against prostate-specific membrane antigen. Hybridoma. 2012;31(6):424\u20139. https:\/\/doi.org\/10.1089\/hyb.2012.0048.","journal-title":"Hybridoma"},{"issue":"2","key":"2285_CR9","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s12033-013-9669-1","volume":"55","author":"H Bakherad","year":"2013","unstructured":"Bakherad H, Gargari SLM, Rasooli I, RajabiBazl M, Mohammadi M, Ebrahimizadeh W, Ardakani LS, Zare H. In vivo neutralization of botulinum neurotoxins serotype E with heavy-chain camelid antibodies (VHH). Mol Biotechnol. 2013;55(2):159\u201367. https:\/\/doi.org\/10.1007\/s12033-013-9669-1.","journal-title":"Mol Biotechnol"},{"issue":"1","key":"2285_CR10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.28991\/SciMedJ-2021-0301-2","volume":"3","author":"M Osipov","year":"2021","unstructured":"Osipov M, Sokolnikov M. Previous malignancy as a risk factor for the second solid cancer in a cohort of nuclear workers. SciMed J. 2021;3(1):8\u201315. https:\/\/doi.org\/10.28991\/SciMedJ-2021-0301-2.","journal-title":"SciMed J"},{"issue":"10","key":"2285_CR11","doi-asserted-by":"publisher","first-page":"4457","DOI":"10.1007\/s00253-012-4518-x","volume":"97","author":"W Ebrahimizadeh","year":"2013","unstructured":"Ebrahimizadeh W, Gargari SM, Rajabibazl M, Ardekani LS, Zare H, Bakherad H. Isolation and characterization of protective anti-LPS nanobody against V. cholerae O1 recognizing Inaba and Ogawa serotypes. Appl Microbiol Biotechnol. 2013;97(10):4457\u201366. https:\/\/doi.org\/10.1007\/s00253-012-4518-x.","journal-title":"Appl Microbiol Biotechnol"},{"issue":"1","key":"2285_CR12","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1128\/AEM.71.1.442-450.2005","volume":"71","author":"E Dolk","year":"2005","unstructured":"Dolk E, Van Der Vaart M, Hulsik DL, Vriend G, de Haard H, Spinelli S, Cambillau C, Frenken L, Verrips T. Isolation of llama antibody fragments for prevention of dandruff by phage display in shampoo. Appl Environ Microbiol. 2005;71(1):442\u201350. https:\/\/doi.org\/10.1128\/AEM.71.1.442-450.2005.","journal-title":"Appl Environ Microbiol"},{"issue":"1\u20132","key":"2285_CR13","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jim.2009.08.016","volume":"350","author":"D Kastelic","year":"2009","unstructured":"Kastelic D, Frkovi\u0107-Grazio S, Baty D, Truan G, Komel R, Pompon D. A single-step procedure of recombinant library construction for the selection of efficiently produced llama VH binders directed against cancer markers. J Immunol Methods. 2009;350(1\u20132):54\u201362. https:\/\/doi.org\/10.1016\/j.jim.2009.08.016.","journal-title":"J Immunol Methods"},{"issue":"3","key":"2285_CR14","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1110\/ps.34602","volume":"11","author":"M Dumoulin","year":"2002","unstructured":"Dumoulin M, Conrath K, Van Meirhaeghe A, Meersman F, Heremans K, Frenken LG, Muyldermans S, Wyns L, Matagne A. Single-domain antibody fragments with high conformational stability. Protein Sci. 2002;11(3):500\u201315. https:\/\/doi.org\/10.1110\/ps.34602.","journal-title":"Protein Sci"},{"issue":"3","key":"2285_CR15","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1007\/s00253-005-0300-7","volume":"72","author":"M Harmsen","year":"2006","unstructured":"Harmsen M, Van Solt C, Van Zijderveld-Van BA, Niewold T, Van Zijderveld F. Selection and optimization of proteolytically stable llama single-domain antibody fragments for oral immunotherapy. Appl Microbiol Biotechnol. 2006;72(3):544\u201351. https:\/\/doi.org\/10.1007\/s00253-005-0300-7.","journal-title":"Appl Microbiol Biotechnol"},{"key":"2285_CR16","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/978-0-387-76643-0_3","volume-title":"Current trends in monoclonal antibody development and manufacturing","author":"GH Ghassabeh","year":"2010","unstructured":"Ghassabeh GH, Muyldermans S. Saerens D (2010) Nanobodies, single-domain antigen-binding fragments of camelid heavy-chain antibodies. In: Shire SJ, Gombotz W, Bechtold-Peters K, Andya J, editors. Current trends in monoclonal antibody development and manufacturing. Newyork: Springer; 2010. p. 29\u201348.https:\/\/doi.org\/10.1007\/978-0-387-76643-0_3"},{"issue":"1\u20132","key":"2285_CR17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jim.2007.04.008","volume":"324","author":"DR Maass","year":"2007","unstructured":"Maass DR, Sepulveda J, Pernthaner A, Shoemaker CB. Alpaca (Lama pacos) as a convenient source of recombinant camelid heavy chain antibodies (VHHs). J Immunol Methods. 2007;324(1\u20132):13\u201325. https:\/\/doi.org\/10.1016\/j.jim.2007.04.008.","journal-title":"J Immunol Methods"},{"issue":"7","key":"2285_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7): e1000097. https:\/\/doi.org\/10.1371\/journal.pmed.1000097.","journal-title":"PLoS Med"},{"issue":"50","key":"2285_CR19","doi-asserted-by":"publisher","first-page":"51965","DOI":"10.1074\/jbc.M409292200","volume":"279","author":"D Saerens","year":"2004","unstructured":"Saerens D, Kinne J, Bosmans E, Wernery U, Muyldermans S, Conrath K. Single domain antibodies derived from dromedary lymph node and peripheral blood lymphocytes sensing conformational variants of prostate-specific antigen. J Biol Chem. 2004;279(50):51965\u201372. https:\/\/doi.org\/10.1074\/jbc.M409292200.","journal-title":"J Biol Chem"},{"issue":"7","key":"2285_CR20","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.2967\/jnumed.115.156729","volume":"56","author":"KL Chatalic","year":"2015","unstructured":"Chatalic KL, Veldhoven-Zweistra J, Bolkestein M, Hoeben S, Koning GA, Boerman OC, de Jong M, van Weerden WM. A novel 111In-labeled anti\u2013prostate-specific membrane antigen nanobody for targeted SPECT\/CT imaging of prostate cancer. J Nucl Med. 2015;56(7):1094\u20139. https:\/\/doi.org\/10.2967\/jnumed.115.156729.","journal-title":"J Nucl Med"},{"issue":"3","key":"2285_CR21","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.bios.2004.11.016","volume":"21","author":"L Huang","year":"2005","unstructured":"Huang L, Reekmans G, Saerens D, Friedt J-M, Frederix F, Francis L, Muyldermans S, Campitelli A, Van Hoof C. Prostate-specific antigen immunosensing based on mixed self-assembled monolayers, camel antibodies and colloidal gold enhanced sandwich assays. Biosens Bioelectron. 2005;21(3):483\u201390. https:\/\/doi.org\/10.1016\/j.bios.2004.11.016.","journal-title":"Biosens Bioelectron"},{"issue":"6","key":"2285_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0127419","volume":"10","author":"X Fan","year":"2015","unstructured":"Fan X, Wang L, Guo Y, Tu Z, Li L, Tong H, Xu Y, Li R, Fang K. Ultrasonic nanobubbles carrying anti-PSMA nanobody: construction and application in prostate cancer-targeted imaging. PLoS ONE. 2015;10(6): e0127419. https:\/\/doi.org\/10.1371\/journal.pone.0127419.","journal-title":"PLoS ONE"},{"issue":"2","key":"2285_CR23","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1089\/cbr.2016.2155","volume":"32","author":"J Nonnekens","year":"2017","unstructured":"Nonnekens J, Chatalic KL, Molkenboer-Kuenen JD, Beerens CE, Bruchertseifer F, Morgenstern A, Veldhoven-Zweistra J, Schottelius M, Wester H-J, van Gent DC. 213Bi-labeled prostate-specific membrane antigen-targeting agents induce DNA double-strand breaks in prostate cancer xenografts. Cancer Biother Radiopharm. 2017;32(2):67\u201373. https:\/\/doi.org\/10.1089\/cbr.2016.2155.","journal-title":"Cancer Biother Radiopharm"},{"issue":"1","key":"2285_CR24","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1039\/D0BM01335H","volume":"9","author":"T Tieu","year":"2021","unstructured":"Tieu T, Wojnilowicz M, Huda P, Thurecht KJ, Thissen H, Voelcker NH, Cifuentes-Rius A. Nanobody-displaying porous silicon nanoparticles for the co-delivery of siRNA and doxorubicin. Biomater Sci. 2021;9(1):133\u201347. https:\/\/doi.org\/10.1039\/D0BM01335H.","journal-title":"Biomater Sci"},{"issue":"14","key":"2285_CR25","doi-asserted-by":"publisher","first-page":"7601","DOI":"10.1021\/acs.jmedchem.0c00418","volume":"63","author":"L Rosenfeld","year":"2020","unstructured":"Rosenfeld L, Sananes A, Zur Y, Cohen S, Dhara K, Gelkop S, Ben Zeev E, Shahar A, Lobel L, Akabayov B. Nanobodies targeting prostate-specific membrane antigen for the imaging and therapy of prostate cancer. J Med Chem. 2020;63(14):7601\u201315. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c00418.","journal-title":"J Med Chem"},{"issue":"6","key":"2285_CR26","doi-asserted-by":"publisher","first-page":"10787","DOI":"10.1002\/jcb.28370","volume":"120","author":"M Hassani","year":"2019","unstructured":"Hassani M, Hajari Taheri F, Sharifzadeh Z, Arashkia A, Hadjati J, van Weerden WM, Modarressi MH, Abolhassani M. Construction of a chimeric antigen receptor bearing a nanobody against prostate a specific membrane antigen in prostate cancer. J Cell Biochem. 2019;120(6):10787\u201395. https:\/\/doi.org\/10.1002\/jcb.28370.","journal-title":"J Cell Biochem"},{"issue":"1","key":"2285_CR27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s40259-019-00392-z","volume":"34","author":"I Jov\u010devska","year":"2020","unstructured":"Jov\u010devska I, Muyldermans S. The therapeutic potential of nanobodies. BioDrugs. 2020;34(1):11\u201326. https:\/\/doi.org\/10.1007\/s40259-019-00392-z.","journal-title":"BioDrugs"},{"issue":"2","key":"2285_CR28","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1080\/08820130902735998","volume":"38","author":"K Omidfar","year":"2009","unstructured":"Omidfar K, Moinfar Z, Sohi AN, Tavangar SM, Haghpanah V, Heshmat R, Kashanian S, Larijani B. Expression of EGFRvIII in thyroid carcinoma: immunohistochemical study by camel antibodies. Immunol Invest. 2009;38(2):165\u201380. https:\/\/doi.org\/10.1080\/08820130902735998.","journal-title":"Immunol Invest"},{"issue":"6","key":"2285_CR29","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1089\/dna.2011.1529","volume":"31","author":"K Omidfar","year":"2012","unstructured":"Omidfar K, Shirvani Z. Single domain antibodies: a new concept for epidermal growth factor receptor and EGFRvIII targeting. DNA Cell Biol. 2012;31(6):1015\u201326. https:\/\/doi.org\/10.1089\/dna.2011.1529.","journal-title":"DNA Cell Biol"},{"key":"2285_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118052","volume":"257","author":"H Bakherad","year":"2020","unstructured":"Bakherad H, Farahmand M, Setayesh N, Ebrahim-Habibi A. Engineering an anti-granulocyte colony stimulating factor receptor nanobody for improved affinity. Life Sci. 2020;257: 118052. https:\/\/doi.org\/10.1016\/j.lfs.2020.118052.","journal-title":"Life Sci"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-021-02285-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-021-02285-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-021-02285-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,30]],"date-time":"2021-10-30T20:17:33Z","timestamp":1635625053000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-021-02285-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,30]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2285"],"URL":"https:\/\/doi.org\/10.1186\/s12935-021-02285-0","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,30]]},"assertion":[{"value":"23 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"580"}}